Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Zentalis Pharmaceuticals Inc shares valued at $7,751,968 were purchased by WALTERS GROUP on Dec 31 ’25. At $1.20 per share, WALTERS GROUP acquired 6,459,973 shares. The insider’s holdings grew to 13,509,973 shares worth approximately $39.85 million following the completion of this transaction.
Also, Matrix Capital Management Comp sold 7,500,000 shares, netting a total of over 9,975,000 in proceeds. Following the sale of shares at $1.33 each, the insider now holds 6,459,973 shares.
Before that, Myers Scott Dunseth had added 21,000 shares to its account. In a trade valued at $29,373, the Director bought Zentalis Pharmaceuticals Inc shares for $1.40 each. Upon closing the transaction, the insider’s holdings increased to 21,000 shares, worth approximately $0.83 million.
As published in a research note from Wedbush on August 12, 2024, Zentalis Pharmaceuticals Inc [ZNTL] has been rated up from an Underperform to a Neutral and the price target has been revised to $4. Analysts at UBS downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in mid June. As of June 18, 2024, Wells Fargo has decreased its “an Overweight” rating to a “an Equal weight” for ZNTL. Earlier on June 18, 2024, Wedbush downgraded its rating. Their new recommendation was “an Underperform” for ZNTL stock which previously was a “a Neutral”.
Analyzing ZNTL Stock Performance
On last trading session, Zentalis Pharmaceuticals Inc [NASDAQ: ZNTL] rose 2.79% to $2.95. The stock’s lowest price that day was $2.8, but it reached a high of $3.07 in the same session. During the last five days, there has been a drop of approximately -15.23%. Over the course of the year, Zentalis Pharmaceuticals Inc shares have jumped approximately 31.70%.
Is Zentalis Pharmaceuticals Inc subject to short interest?
Stocks of Zentalis Pharmaceuticals Inc saw a sharp steep in short interest on 2025-12-31 dropping by -1.02 million shares to 4.11 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 5.13 million shares. A decline of -24.76% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.4 of the overall float, the days-to-cover ratio (short ratio) decline to 5.4.
Which companies own the most shares of Zentalis Pharmaceuticals Inc (ZNTL)?
In terms of Zentalis Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 2 in the next 12 months, down nearly -30.31% from the previous closing price of $2.87. Analysts anticipate Zentalis Pharmaceuticals Inc stock to reach 2 by 2026, with the lowest price target being 2. In spite of this, 10 analysts ranked Zentalis Pharmaceuticals Inc stock as Buy at the end of 2026. On June 18, 2024, Morgan Stanley assigned a price target of “an Equal-weight” to the stock and downgraded coverage with a $8.
